Investor Presentation Full Year 2021
74
Investor presentation Full year 2021
Scientific excellence ensures an innovative and competitive
pipeline with therapeutic solutions for severe conditions.
Innovation in haemophilia
More than 35 years of innovation
EsperoctⓇ
Refixia®
NovoEight®
NovoThirteenⓇ
NovoSevenⓇ
Mim8
Concizumab
Non-invasive
therapy
Biopharm pipeline
Curative
therapy
Current
phases
2018
2019
2020
2021
2022
Phase 3a
Phase 3a
Phase 1
EPI01 (SCD)
Phase 1/2
Phase 3
Concizumab
HA and HB1
Concizumab HAWI/HBWI¹
Mim8
Phase 3
Somapacitan GHD
Phase 2
Somapacitan SGA²
1986
Today
Future
1 The concizumab phase 3 programme was resumed in August 2020.
SCD: Sickle-cell disease; SGA: Short of gestational age; HwI: Haemophilia A or B patients with inhibitors; SGA: small for gestational age; GHD: Growth hormone deficiency
2Phase 3 trial also on-going for indications ISS, Turner, Noon and SGA. 3 Mim8 phase 3 programme goes beyond 2022
Mim83
Novo NordiskⓇView entire presentation